Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis
Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and ...
Hosted on MSN1h
Eli Lilly pays $10m upfront for Organovo’s FXR agonist
Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...
Why Madrigal Pharmaceuticals Stock Is Soaring Today
Shares of Madrigal Pharmaceuticals ( MDGL 16.35%) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain ...
Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...
Madrigal reports ‘positive’ results from Phase 3 MAESTRO-NAFLD-1 trial
Madrigal Pharmaceuticals (MDGL) reported positive two-year results from the open-label compensated MASH cirrhosis arm of the Phase 3 ...
Zacks.com on MSN4h
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Madrigal Pharmaceuticals MDGL reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus ...
BioPharma Dive4h
AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch
The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...
clinicaladvisor.com20d
Rezdiffra for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
In March 2024, the US Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra™ (resmetirom) in conjunction with diet and exercise for the treatment of adults with ...
Madrigal Pharmaceuticals reports Q4 EPS ($2.71), consensus ($4.12)
Reports Q4 revenue $103.3M, consensus $97.81M. Bill Sibold, Chief Executive Officer of Madrigal, stated, “Looking back on 2024, I’m incredibly ...
FDA approvals decline but drug innovation remains strong even among small sponsors
Approvals last year included rare disease treatments, new oncology drugs, Eli Lilly’s Kisunla, and Mesoblast's Ryoncil.
Nasdaq1mon
Madrigal Pharmaceuticals Reports Preliminary 2024 Net Sales and Patient Milestones for Rezdiffra™
Madrigal Pharmaceuticals provided an update on its financial performance, revealing preliminary fourth-quarter and full-year 2024 net sales for Rezdiffra™ (resmetirom) projected between $100 ...
Madrigal Pharma stock jumps on positive trial results and revenue beat
Investing.com -- Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: NASDAQ: MDGL) rose 17% following the announcement of their fourth-quarter and full-year 2024 financial results, which included a ...